On Monday, X4 Pharmaceuticals Inc (NASDAQ: XFOR) opened lower -12.63% from the last session, before settling in for the closing price of $2.85. Price fluctuations for XFOR have ranged from $1.35 to $26.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 47.41%. Company’s average yearly earnings per share was noted 58.89% at the time writing. With a float of $8.00 million, this company’s outstanding shares have now reached $11.41 million.
Let’s determine the extent of company efficiency that accounts for 143 employees. In terms of profitability, gross margin is 83.0%, operating margin of -323.09%, and the pretax margin is -310.1%.
X4 Pharmaceuticals Inc (XFOR) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of X4 Pharmaceuticals Inc is 29.88%, while institutional ownership is 13.41%. The most recent insider transaction that took place on May 16 ’25, was worth 2,561. In this transaction Chief Commercial Officer of this company bought 1,032 shares at a rate of $2.48, taking the stock ownership to the 25,337 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Chief Commercial Officer bought 13,404 for $0.34, making the entire transaction worth $4,598. This insider now owns 129,173 shares in total.
X4 Pharmaceuticals Inc (XFOR) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -5.4 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -5.16) by -0.24. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.89% per share during the next fiscal year.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
Check out the current performance indicators for X4 Pharmaceuticals Inc (XFOR). In the past quarter, the stock posted a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -14.80, a number that is poised to hit -3.25 in the next quarter and is forecasted to reach -1.33 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
Looking closely at X4 Pharmaceuticals Inc (NASDAQ: XFOR), its last 5-days average volume was 37.11 million, which is a jump from its year-to-date volume of 1.6 million. As of the previous 9 days, the stock’s Stochastic %D was 70.32%.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 15.85%, which indicates a significant decrease from 54.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.36 in the past 14 days, which was lower than the 0.42 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.12, while its 200-day Moving Average is $9.19. However, in the short run, X4 Pharmaceuticals Inc’s stock first resistance to watch stands at $2.98. Second resistance stands at $3.46. The third major resistance level sits at $3.71. If the price goes on to break the first support level at $2.25, it is likely to go to the next support level at $2.00. Now, if the price goes above the second support level, the third support stands at $1.52.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
There are currently 5,789K shares outstanding in the company with a market cap of 28.40 million. Presently, the company’s annual sales total 2,560 K according to its annual income of -37,450 K. Last quarter, the company’s sales amounted to 1,970 K and its income totaled -25,740 K.
